BPC-157 Benefits: What the Research Shows
Last reviewed
BPC-157 is sold online with long lists of benefits, from tendon healing to gut repair. Here's what the research behind those claims actually is, and how much of it was done in people.
The short version
- Nearly all BPC-157 research is in animals and lab models.
- A 2025 systematic review found one human study: 12 patients, no control group.
- Its safety in people is unknown, it isn't FDA-approved, and it's banned for tested athletes.
Evidence at a glance
| Type of study | What exists |
|---|---|
| Lab and animal | Many studies, in models of tissue injury, inflammatory bowel disease and nervous system conditions. A 2025 sports-medicine review counted 35 preclinical studies on musculoskeletal healing alone. |
| Human trials | Very limited One retrospective review of 12 patients. A registered phase 1 safety trial has had unknown status since 2016, with no published results. |
| Human safety data | None The 2025 review found no study that assessed BPC-157's safety or side effects in people. |
What BPC-157 is
BPC-157 is a synthetic peptide of 15 amino acids, based on a sequence first isolated from human gastric juice. It was first described by a research group in Croatia in 1993, and much of the published research comes from that same group.
The claimed benefits, and where they come from
The benefits you'll see listed online, faster healing of tendons, ligaments, muscle and gut lining, trace back to animal and lab studies. A 2025 literature and patent review describes the research as focused mainly on preclinical models of tissue injury, inflammatory bowel disease and nervous system disorders, and notes that regulators haven't approved BPC-157 because human clinical evidence is lacking.
The one human study
A 2025 systematic review in the HSS Journal looked for every study of BPC-157 in orthopaedic sports medicine. Of 36 studies, 35 were preclinical. The only clinical one was a retrospective review of 12 patients with chronic knee pain who'd received a single injection into the knee; 7 reported improvement lasting more than six months.
That's a small, uncontrolled look back at patients' reports, not a trial. There was no placebo group, so it can't separate the peptide's effect from natural recovery or the placebo effect. The review concluded that clinical safety in humans remains unknown and that clinicians and athletes should exercise caution.
Is it safe?
Nobody can say yet. USADA notes a concerning lack of published human clinical trial data, and the 2025 review found no study of side effects in people. "Unknown" isn't the same as "dangerous," but it means any risks haven't been measured. More in Are peptides safe?
FDA status and sports rules
BPC-157 isn't FDA-approved for any use. The FDA removed it from its compounding "significant safety concerns" list in April 2026, and an advisory committee recommended it for the list of ingredients compounding pharmacies can use in July 2026, against the advice of FDA staff. The FDA hasn't acted on that recommendation. Latest status: FDA status tracker.
For athletes, BPC-157 is on the 2026 World Anti-Doping Code Prohibited List in class S0, non-approved substances, prohibited at all times.
Frequently asked questions
What are the benefits of BPC-157?
In animal and lab studies it has been studied for tissue injuries, inflammatory bowel disease and nervous system conditions. In people, a 2025 review found one 12-patient study with no control group.
Is BPC-157 proven in humans?
No. There's one small retrospective study and no published human safety study.
Is BPC-157 FDA approved?
No. An advisory committee recommended it for compounding in July 2026; the FDA hasn't acted.
How do people mix BPC-157?
It's sold as a powder that's reconstituted with water. Our BPC-157 reconstitution calculator does the arithmetic; it doesn't recommend an amount.
Sources
- Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review, HSS Journal (2025)
- Józwiak et al., Multifunctionality and possible medical application of the BPC 157 peptide, Pharmaceuticals (2025)
- USADA: BPC-157, what athletes should know
- The 2026 Prohibited List, World Anti-Doping Code (official Dutch government publication)
- Goodwin: FDA's 2026 peptide compounding changes
- Frier Levitt: FDA advisory committee peptide vote (2026)